RALEIGH-DURHAM, N.C., May 11, 2016 /PRNewswire/ -- Kineticos, in partnership with Ipsos Healthcare and Demy-Colton, today announced the Q1 2016 results of the Biopharma CEO Confidence Index, a forward-looking indicator designed to measure C-suite sentiment and confidence in the biopharma industry's economy.
67 biopharma CEOs were surveyed in the Q1 study and the data indicates CEO confidence has leveled off after expressing some uncertainty in Q4 of last year. Here are a few highlights from the Q1 Biopharma CEO Confidence Index:
- CEOs who were very confident in their ability to raise capital in the next 18 months, rose from 39% in Q4 to 42% in Q1
- CEOs who viewed the current deal landscape as good declined for a second straight quarter. (82% --> 61% --> 45%)
- Confidence in delivering clinically differentiated assets remains high (69% in Q4 and 72% in Q1)
- CEO's who were very confident in the regulatory environment increased slightly from 24% in Q4 to 22% in Q1.
- CEOs planning to commercialize with external partners vs. independently, increased (61% in Q4 to 70% in Q1).
- The 2 largest risks among CEOs remain access to capital (40%) and clinical results (30%).
A more extensive summary and analysis of the Q1 2016 Biopharma CEO Confidence Index is available at www.BiopharmaCEOConfidenceIndex.com.
Executives from all three partner organizations were asked to comment on the Q1 results.
"This research highlights that CEOs are becoming more harmonized in their views on the market and related opportunities, suggesting greater overall stability and underlying confidence about the future direction of their business," noted Steve Girling, President of Ipsos Healthcare.
Sara Demy of Demy-Colton commented on the overall state of the Biopharma CEO Confidence Index. "Our goal in creating this index was to use it as a forward-looking indicator. Now that we have 3 quality data sets, I'm excited to be able to start identifying trends and using the data to anticipate fluctuations in the marketplace.
Shailesh Maingi, CEO of Kineticos, offered his perspective on the behavior patterns of biopharma CEOs. "Biopharma CEOs by their nature are entrepreneurial and have a high risk tolerance. They know that R&D is difficult and a long term perspective is necessary for success. The Biopharma CEO Confidence Index further validates our belief that biopharma CEOs take the ups and downs of the capital markets in stride."
About the Biopharma CEO Confidence Index
The Biopharma CEO Confidence Index is the first and only forward-looking indicator designed to measure C-suite sentiment and confidence in the biopharma industry's economy. This confidence—or lack thereof—is defined by the degree of optimism within six key business indicators, including:
- Capital Markets
- Deal Landscape
- Clinical Development
- Regulatory Affairs
- Business Model and Workforce
Measuring confidence through these indicators over time will demonstrate an ebb and flow of market dynamics and confidence in the future success of companies and growth in the overall market.
Kineticos is a specialized management consulting firm serving the life science industry.
The firm is focused on identifying opportunities to drive strategic growth and achieve operational excellence for its clients. Through its practice areas, the firm has experience working with companies across the life science industry ecosystem. For more information on Kineticos and its capabilities, please visit www.kineticos.com.
About Ipsos Healthcare
Ipsos Healthcare is a fact-based research, consulting and strategy specialist in the global biopharmaceutical industry. For more information, please visit www.ipsos.com/marketing/healthcare.
Demy-Colton produces highly specialized investor and business conferences exclusively for the biopharmaceutical and life sciences industry. For more information, please visit www.demy-colton.com.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/confidence-stabilizes-in-the-q1-biopharma-ceo-confidence-index-300266581.html